LEXINGTON, Mass., June 4 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that based on a recent discussion with the U.S. Food and Drug Administration (FDA) regarding the ...

LEXINGTON, Mass., June 4 -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV - News) today announced that based on a recent discussion with the U.S. Food and Drug Administration (FDA) regarding the NDA ...

LEXINGTON, Mass., Sept. 26 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that it has reached agreement with the U.S. Food and ...

Shares of Indevus Pharmaceuticals Inc. plunged nearly 70 percent after the company reported at least a two-year setback for Nebido, its three-month formulation of testosterone, for male hypogonadism ...

LEXINGTON, Mass. Indevus Pharmaceuticals expects the Food and Drug Administration to request additional safety data on the firm’s testosterone drug Nebido, delaying a ruling on the product’s approval ...

Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate therapy for male hypogonadism. This ...

Please provide your email address to receive an email when new articles are posted on . Men with severe hypogonadism reported improved sexual function after testosterone replacement therapy with ...

Endo Pharmaceuticals and Indevus Pharmaceuticals have announced that the FDA has accepted for review their complete response submission to the New Drug Application (NDA) for Nebido (testosterone ...

South Korea’s best-known swimmer faces a possible career-ending ban after he failed a recent doping test. Four-time Olympic medalist Park Tae-hwan has blamed the positive result on a Nebido injection ...